Loading clinical trials...
Loading clinical trials...
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs).
Conditions
Locations
1
United States
University of Colorado Anschutz
Aurora, Colorado, United States
Start Date
July 1, 2014
Primary Completion Date
December 1, 2018
Completion Date
January 1, 2019
Last Updated
April 17, 2019
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
University of Colorado, Denver
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions